Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies

The main systemic therapy for the management of hormone-sensitive prostate cancer (PC) is androgen deprivation therapy (ADT), with the use of long-acting luteinizing hormone releasing-hormone (LHRH) agonists considered the main form of ADT used in clinical practice to obtain castration in PC. The co...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciarra, Alessandro, Busetto, Gian Maria, Salciccia, Stefano, Del Giudice, Francesco, Maggi, Martina, Crocetto, Felice, Ferro, Matteo, De Berardinis, Ettore, Scarpa, Roberto Mario, Porpiglia, Francesco, Carmignani, Luca, Damiano, Rocco, Artibani, Walter, Carrieri, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237856/
https://www.ncbi.nlm.nih.gov/pubmed/34194398
http://dx.doi.org/10.3389/fendo.2021.695170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237856/
https://www.ncbi.nlm.nih.gov/pubmed/34194398
http://dx.doi.org/10.3389/fendo.2021.695170

Ejemplares similares